Safinamide for the treatment of Parkinson’s disease

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525-35
   PubMed Web of Science ®Google Scholar
• Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol 2006;15(Suppl 1):14-20
   Google Scholar
• Hornykiewicz O. Biochemical aspects of Parkinson’s disease. Neurology 1998;51(Suppl 2):S2-9
   PubMed Web of Science ®Google Scholar
• Braak H, Del TK, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2004;24:197-211
   Web of Science ®Google Scholar
• Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010;120(2):131-43
   PubMed Web of Science ®Google Scholar
• Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med 2010;16(6):653-61
   PubMed Web of Science ®Google Scholar
• Borgohain R, Kandadai RM. Safinamide: a novel anti-Parkinsonian drug with multiple actions. Neurodegener Dis Manag 2013;3:231-40
   Google Scholar
• Stacy M. Medical treatment of Parkinson disease. Neurol Clin 2009;27(3):605-31
   PubMed Web of Science ®Google Scholar
• Nutt JG. Motor fluctuations and dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 2001;8(2):101-8
   PubMed Web of Science ®Google Scholar
• Ondo WG. Motor complications in Parkinson’s disease. Int J Neurosci 2011;121(Suppl 2):37-44
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22(10):1379-89
   PubMed Web of Science ®Google Scholar
• Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007;83(980):384-8
   PubMed Web of Science ®Google Scholar
• Stansley BJ, Yamamoto BK. L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology 2013;67:243-51
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 2003;5:165-76
   PubMed Web of Science ®Google Scholar
• Fahn S. Levodopa in the treatment of Parkinson’s disease. J Neural Transm Suppl 2006;71:1-15
   Google Scholar
• Parkkinen L, O’Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011;77(15):1420-6
   PubMed Web of Science ®Google Scholar
• Rasmussen VG, Østergaard K, Dupont E, Poulsen SH. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists. Mov Disord 2011;26(5):801-6
   PubMed Web of Science ®Google Scholar
• Pellicano C, Benincasa D, Fanciulli A, et al. The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study. Eur J Med Res 2013;18:60
   PubMed Web of Science ®Google Scholar
• Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clin Neuropharmacol 2008;31(1):51-6
   PubMed Web of Science ®Google Scholar
• Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009;72(7 Suppl):S44-50
   PubMed Web of Science ®Google Scholar
• Chau KY, Cooper JM, Schapira AH. Pramipexole reduces phosphorylation of α-synuclein at serine-129. J Mol Neurosci 2013;51(2):573-80
   PubMed Web of Science ®Google Scholar
• Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013;12(8):747-55
   PubMed Web of Science ®Google Scholar
• Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M. A systematic review of catechol-o-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 2012;35(4):185-90
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68(1):18-27
   PubMed Web of Science ®Google Scholar
• Müller T. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clin Neuropharmacol 2013;36(3):84-91
   PubMed Web of Science ®Google Scholar
• Caslake R, Macleod A, Ives N, et al. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson’s disease. Cochrane Database Syst Rev 2009;2009(4): CD006661
   Google Scholar
• Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 2010;2010(7): CD007166
   Google Scholar
• Zagmutt FJ, Tarrants ML. Indirect comparisons of adverse events and dropout rates in early Parkinson’s disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci 2012;122(7):345-53
   PubMed Web of Science ®Google Scholar
• Hauser RA, Silver D, Choudhry A, for the ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord 2014; doi: 10.1002/mds.25877. [Epub ahead of print]
   Web of Science ®Google Scholar
• Boll MC, Alcaraz-Zubeldia M, Rios C. Medical management of Parkinson’s disease: focus on neuroprotection. Curr Neuropharmacol 2011;9(2):350-9
   PubMed Web of Science ®Google Scholar
• Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110:509-15
   PubMed Web of Science ®Google Scholar
• Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann NY Acad Sci 2000;899:255-61
   PubMed Web of Science ®Google Scholar
• Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease. Neurology 2006;66:S69-79
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lew MF, Hurtig HI, TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord 2009;24(4):564-73
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003;2003(2): CD003735
   Google Scholar
• Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol 2010;9(11):1106-17
   PubMed Web of Science ®Google Scholar
• Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord 2008;23(Suppl 3):S599-612
   PubMed Web of Science ®Google Scholar
• Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003(2):CD003467
   PubMedGoogle Scholar
• Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One 2010;5(12):e15298
   PubMed Web of Science ®Google Scholar
• Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301(1):63-73
   PubMed Web of Science ®Google Scholar
• Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord 2009;15(10):728-41
   PubMed Web of Science ®Google Scholar
• Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004;50:77-85
   PubMed Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848-52
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(Suppl 2):S18-23
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol 2003;26(4):213-17
   PubMed Web of Science ®Google Scholar
• Marquet A, Kupas K, Johne A, et al. The effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther 2012;92(4):450-7
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(7 Suppl 2):S24-9
   PubMed Web of Science ®Google Scholar
• Schapira AH. Safinamide in the treatment of Parkinson’s disease. Expert Opin Pharmacother 2010;11(13):2261-8
   PubMed Web of Science ®Google Scholar
• Chazot PL. Safinamide for the treatment of Parkinson’s disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs 2007;8(7):570-9
   PubMedGoogle Scholar
• Caccia C, Salvati P, Rossetti S, Anand R. Safinamide: modulation of dopaminergic and glutamatergic systems. Mov Disord 2008;67:S22-3
   Google Scholar
• Grégoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 2013;19(5):508-14
   PubMed Web of Science ®Google Scholar
• . Vaghi F, Maj R, Rosa B, et al.Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils. Soc Neurosci Abstr 1997;23:545
   Google Scholar
• Kupsch A, Sautter J, Götz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001;108(8-9):985-1009
   PubMed Web of Science ®Google Scholar
• Maj R, Fariello RG, Ukmar G, et al. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol 1998;359(1):27-32
   PubMed Web of Science ®Google Scholar
• Morsali D, Bechtold D, Lee W, et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 2013;136(Pt 4):1067-82
   PubMed Web of Science ®Google Scholar
• Tsai SY, Rothman RK, Su TP. Insights into the sigma-1 receptor chaperone’s cellular functions: a microarray report. Synapse 2012;66(1):42-51
   PubMed Web of Science ®Google Scholar
• Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology 2013;92(3-4):207-16
   PubMed Web of Science ®Google Scholar
• Fariello RG. Safinamide. Neurotherapeutics 2007;4:110-16
   PubMed Web of Science ®Google Scholar
• Krösser S, Marquet A, Gallemann D, et al. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos 2012;33(9):550-9
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;24:63(4):746-8
   Google Scholar
• Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord 2012;27(1):106-12
   PubMed Web of Science ®Google Scholar
• Schapira AH, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol 2013;20(2):271-80
   PubMed Web of Science ®Google Scholar
• Barone P, Fernandez H, Ferreira J, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Presented at the 65th American Academy of Neurology annual meeting held at San Diego, March, 2013, Neurology 2013. 80:P01.061-1
   Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 2014;29(2):229-37
   PubMed Web of Science ®Google Scholar
• Borgohain, R, Szasz J, Stanzione P, et al. Two year placebo- controlled safety and tolerability data for safinamide as add on to levodopa in patients with Parkinson’s disease (PD). Presented at the XIX WFN World Congress on Parkinson’s Disease and Related Disorders - Shanghai, China, December 11–14, 2011. Parkinsonism Relat Disord 2012;18(Suppl 2):S132
   Google Scholar
• Anand R, Borgohain R, Stocchi F, et al. First 2-year, placebo-controlled study in Parkinson’s disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia. Presented at the XIX WFN World Congress on Parkinson’s Disease and Related Disorders - Shanghai, China, December 11-14, 2011. Parkinsonism Relat Disord 2012;18(Suppl 2):S132-3
   PubMedGoogle Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of Safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 2014; 29(10):1273-80
   Web of Science ®Google Scholar
• Schapira AH, Fox S, Hauser R, et al. Safinamide add on to L-dopa: a randomized, placebo-controlled 24-week global trial in patients with Parkinson’s disease and motor fluctuations (SETTLE). Presented at the 65th American Academy of Neurology annual meeting held at San Diego, March, 2013, Neurology 2013. 80:P01.1062-2
   Google Scholar
• Sharma T, Anand R, Stocchi F, et al. Cognitive effects of safinamide in early Parkinson’s disease (PD) patients. Presented at the 11th International Parkinson’s disease and other movement disorders congress held at Istanbul, Turkey, 2007. Mov Disord 2007;22(Suppl 16):S236
   Google Scholar
• Duty S, Jenner P. Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011;164(4):1357-91
   PubMed Web of Science ®Google Scholar
• Safinamide as add-on therapy in patients with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist. Available from: http://clinicaltrials.gov/show/NCT00643045
   Google Scholar
• Safinamide as add-on therapy in patients with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist (12 month extension). Available from: http://clinicaltrials.gov/show/NCT00642889
   Google Scholar
• MOTION, safinamide in early IPD, as add-on to dopamine agonist. Available from: http://clinicaltrials.gov/show/NCT00605683
   Google Scholar
• Efficacy and safety of safinamide (50 and 100 mg/day) versus placebo, in patients with mid-late stage Parkinson’s disease. Available from: http://clinicaltrials.gov/show/NCT01187966
   Google Scholar
• 18-month study of long-term efficacy & safety of safinamide as add-on therapy in patients with mid-late stage PD. Available from: http://clinicaltrials.gov/show/NCT01286935
   Google Scholar
• Safinamide in idiopathic Parkinson’s disease (IPD) with motor fluctuations, as add-on to Levodopa (SETTLE). Available from: http://clinicaltrials.gov/show/NCT00627640
   Google Scholar